Semaglutide Reduces Inflammation Biomarkers in American Males: A Three-Year Study
Reading Time: 2 minutesIntroduction Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been primarily recognized for its efficacy in managing type 2 diabetes and aiding weight loss. However, recent research has begun to explore its broader health benefits, particularly in reducing systemic inflammation. This article delves into a three-year study examining the effects of semaglutide on inflammation biomarkers in American males, offering insights... Read more »
